Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients.
BACKGROUND
Matrix metalloproteinase 7 (MMP-7) is involved in invasion, metastasis, growth, and angiogenesis. The aim of this study is to assess the prognostic role of serum MMP-7 in curatively resected colorectal cancer (CRC).


METHODS
Patients undergoing resection for CRC (n = 175) were recruited from July 2003 to December 2004. MMP-7 was determined using a quantitative solid phase sandwich ELISA. Cox analysis was used to assess the role of MMP-7 in predicting overall survival (OS) and disease-free survival (DFS).


RESULTS
The median length of follow-up was 45 months (range 1 to 59). Levels of MMP-7 are predictors of DFS (hazard ratio [HR] 1.119, 95% confidence interval [95% CI] 1.038-1.207) and of OS (HR 1.113, 95% CI 1.025-1.209). Patients with MMP-7 higher than the median (4.3 ng/ml) are more likely to relapse (29.5% vs 18.4%, P = .084); median time to progression in relapsed patients is 8 months if MMP-7 is > or =4.3 ng/ml and 18 months if MMP-7 is <4.3 ng/ml. Node-negative patients with low MMP-7 have a predicted probability of relapse-free survival at 4 years of 88% (95% CI 83-92%); if the MMP-7 is higher than the median value; this probability is 77% (95% CI 73-81%).


CONCLUSIONS
MMP-7 predicts recurrence in curatively resected CRC patients.
Martínez-Fernandez
Alejandro
A
Department of Medical Oncology, Hospital Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Médica de Enfermedades Hepáticas y Digestivas, University of Barcelona, Barcelona, Catalonia, Spain.
García-Albeniz
Xabier
X
Pineda
Estela
E
Visa
Laura
L
Gallego
Rosa
R
Codony-Servat
Jordi
J
Augé
Josep Maria
JM
Longarón
Raquel
R
Gascón
Pere
P
Lacy
Antonio
A
Castells
Antoni
A
Maurel
Joan
J
D000230:Adenocarcinoma / Q000097:blood* / Q000401:mortality / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D003082:Colectomy; D015179:Colorectal Neoplasms / Q000097:blood* / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D020783:Matrix Metalloproteinase 7 / Q000097:blood*; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D020783:Matrix Metalloproteinase 7